A substudy of the PROMISE trial demonstrates that quantitative plaque measures on CCTA—specifically total and noncalcified plaque burden—independently predict major adverse cardiovascular events in symptomatic outpatients, offering a precision medicine approach beyond traditional clinical risk scores.